Alignment Health Appoints Adnan Mansour as Chief Digital Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Alignment Health announced the appointment of Adnan Mansour as chief digital officer. Effective Jan. 19, Mansour reports to Alignment Health founder and CEO John Kao.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALHC
Wall Street analysts forecast ALHC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALHC is 21.81 USD with a low forecast of 18.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 22.080
Low
18.00
Averages
21.81
High
30.00
Current: 22.080
Low
18.00
Averages
21.81
High
30.00
About ALHC
Alignment Healthcare, Inc. is a consumer-centric platform designed to improve the healthcare experience for seniors. The Company’s operations primarily consist of Medicare Advantage Plans in the states of California, North Carolina, Nevada, Arizona, Florida and Texas. It partners with local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology (AVA). AVA’s capabilities include consumer experience, internal care delivery, external providers, health plan operations and growth operations. AVA offers a digital ecosystem that enables its members and their support system to get the information and care they need, when and how they need it. With their AVA-powered member portal and mobile app, seniors have many self-service capabilities and can get 24/7 care, send secure messages to their concierge and care teams, check their rewards and ACCESS On-Demand Concierge Card balance, and view their health history.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Astrana Health Stock Plummets 22% Amid Medicare Payment Concerns
- Significant Stock Drop: Astrana Health Inc. shares fell approximately 22% to close at $21.48 on Tuesday, primarily due to CMS's proposed 0.09% payment growth for Medicare Advantage in 2027, indicating weak payment growth that could impact future revenues.
- High Revenue Dependency: Analysts noted that Medicare accounts for about 61% of Astrana Health's revenue, and despite the sharp decline, the stock's drop was more severe than peers like Agilon Health and Alignment Healthcare, which fell around 10% and 12%, respectively, reflecting greater market concerns about Astrana.
- Differentiated Risk Adjustment Practices: Analyst William Blair highlighted that Astrana Health's risk adjustment practices differ from larger payers, relying on direct patient care rather than audio-only visits or standalone chart reviews, resulting in lower exposure to the risk score impacts proposed by CMS.
- Long-Term Value Potential: Despite short-term pressures, analysts believe that CMS's proposals could enhance the company's long-term value, as payers will need to rely on fully delegated care delivery partners to manage patients and costs, potentially leading to more delegated contract agreements in 2027 and beyond.
Continue Reading
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
Continue Reading